Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cedarburg Hauser Pharmaceuticals has expanded production capacity at its manufacturing facility in Wisconsin, US, to meet the increased demand for contract of commercial active pharmaceutical ingredients (APIs).
Subscribe to our email newsletter
The company, which is a contract development and manufacturing organization, said the expansion was also carried out to improve safety and GMP systems.
Cedarburg Hauser operations director John Flahive said the improvements increase the company’s total reactor capacity by nearly 50%.
"We have also added a reactor and chiller that allow for cryogenic reactions in our GMP labs," Flahive added.
In addition to the new reactors, the company made improvements to the air handling systems in the GMP manufacturing suites, equipped a reverse osmosis water system, improved isolation capabilities, and upgraded its Emerson DeltaV digital automation system.
Cedarburg Hauser CEO Tony Laughrey said the flexibility afforded by the additional reactor capacity allows the company to better meet its customer’s on-time and on-budget requirements
"We will continue to invest in our business as we strive to be the premier contract API manufacturer," Laughrey added.